Long-Term Reduction of Relapse Rate and Confirmed Disability Progression After 6 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis

Riadh Gouider, Gavin Giovannoni, Ludwig Kappos, Stephen L. Hauser, Xavier Montalban, Harold Koendgen, Kalpesh Prajapati, Marianna Manfrini, Jerry S. Wolinsky